AFT Pharmaceuticals Limited (AFT.NZ) Stock Analysis & Winston Score

AFT Pharmaceuticals is a New Zealand-based drug company that develops and sells prescription and over-the-counter medicines. Its products include pain relievers, cold and flu treatments, and specialty pharmaceuticals sold to hospitals, pharmacies, and consumers. The company is best known for Maxigesic, a combination painkiller it developed in-house and has licensed to partners in dozens of countries around the world. AFT makes money through direct product sales in its home markets of New Zealand and Australia, plus royalty and licensing fees from international partners who sell Maxigesic under their own brands. It operates primarily across Australasia but has licensing agreements spanning over 100 countries, giving it global reach without needing to build its own sales force everywhere. The key growth driver is continued international expansion of Maxigesic, though the main risk is dependence on a single flagship product — if that drug faces generic competition or loses key licensing deals, revenue could be significantly affected.